ONKOLOGIE www.onkologiecs.cz 100 MONOKLONÁLNÍ GAMAPATIE Waldenströmova makroglobulinemie, klinické příznaky, přehled léčebných možností a vlastní zkušenosti s léčbou ibrutinibem 45. Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM et al. Characterization of cryoglobulins by immunoblotting. Clin Chem. 1992;38(6):798-802. 46. Sargur R, White P, Egner W. Cryoglobulin evaluation: best practice? Ann Clin Biochem. 2010;47:8-16. 47. Vermeersch P, Gijbels K, Mariën G, Lunn R, Egner W, White P, Bossuyt X. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem. 2008;54(1):39-43. 48. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110-115. 49. Gerz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Amer J Hematol. 2021;96(2):258-269. 50. Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. 51. Elba S, Castellino A, Soriasio R, et al. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. J Med Case Rep. 2020;14(1):75. doi: 10.1186/ s13256-020-02380-2. 52. Jelínek T, Bezděkova R, Zátopková M, et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017;7(10):e617. doi: 10.1038/ bcj.2017.90. 53. Wang W, Lin P. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia:clinicopathological features and differential diagnosis. Pathology. 2020;52(1):6-14. doi: 10.1016/j.pathol.2019.09.009. 54. Baďurová K, Gregorová J, Vlachová M, et al. Waldenströmova makroglobulinemie. Klin. onkol. 2021;34(6):428-433. 55. Sedlaříková L, Sadílková K, Bešše L, et al. Cytokinové profily mnohočetného myelomu a Waldenströmovy makroglobulinemie. Klin. Onkol. 2014;(27):18-23. 56. Growková K, Chyra Z, Jelínek T, et al. Diagnostic tools of Waldenström’s macroglobulinemia – best possibilities for non-invasive and long-term disease monitoring. Klin. onkol. 2017;30(Suppl. 2):81-91. 57. Kutálková K, Sedlaříková L, Ševčíková S, et al. Genetické změny u Waldenströmovy makroglobulinemie. Vnitř. lék. 2016;62(1):40-43. 58. Ševčíková S, Novák L, Bešše L, et al. Molekulární podstata Waldenströmovy makroglobulinemie. Klin. onkol. 2012; 25(6):413-420. 59. Ranjit Banwait,Kevin O‘Regan,Federico Campigotto, et al. The role of 18F-FDG PET/CT imaging in Waldenstrommacroglobulinemia. American J. Hematology. 2011;86(7):567-572. https://doi.org/10.1002/ajh.22044. 60. Kaščák M, Hájek R, Minařík J, et al. Diagnostika a léčba Waldenströmovy makroglobulinémie. Transfuze a Hematologie dnes. 2022;28(Suppl.1)S44-S74. 61. Leleu X, Xie W, Bagshaw M, Banwait R. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clin Cancer Res. 2011;17(9):3013-3018. doi: 10.1158/1078-0432.CCR-10-2954. 62. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1104-1107. doi: 10.1080/10428190802074619. 63. Itzykson R, Le Garf f-Tavernier M, Katsahian S, et al. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom‘s macroglobulinemia. Haematologica. 2008;93(5):793-794. doi: 10.3324/haematol.12107. 64. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7(11):e827-e837. doi:10.1016/S23523026(20)30224-6. 65. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom‘s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737-742. 66. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301-307. 67. Souchet L, Levy V, Ouzegdouh M, et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom‘s macroglobulinemia. Am J Hematol. 2016;91:782-786. 68. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenstrom macroglobulinemia: a meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol. 2016;105:118-126. 69. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol. 2009;22:480-485. 70. Lunn MP. Neuropathies and paraproteins. Curr Opin Neurol. 2019;32(5):658-665. doi: 10.1097/WCO.0000000000000726. 71. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M ‚flare‘ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:25932598. 72. Rummel MJ, Lerchenmüller C, Hensel M, et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström‘s Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study. Blood. 2019;134:343-343. 73. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344-3349. 74. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126:1392-1394. 75. Mössner E, Brünker P, Moser P, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood. 2010;115(22):4393-4402. 76. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia. Blood. 2016;128(10):13211328. 77. Gavriatopoulou M, Kastritis E, Kyrtsonis MC, et al. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refraktory Waldenström’s macroglobulinemia. Leuk Lymphoma. 2017;58(6):1506-1508. 78. Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenström’s macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017;4(1):e24-e34. 79. Buske C. Ofatumumab: another way to target CD20 in Waldenström’s macroglobulinaemia? Lancet Haematol. 2017;4(1):e4-e5. 80. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042. 81. Adam Z, Krejčí M, Pour L, et al. Obinutuzumab v léčbě pacientky s Waldenströmovou makroglobulinémií netolerující rituximab – popis případu Transfuze a hematologie dnes. 2021;27(2):160-165. 82. Tomowiak C, Poulain S, Herbaux C, et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed/ refractory Waldenström macroglobulinemia. Blood Adv. 2021;5(9):2438-2446. doi: 10.1182/bloodadvances.2020003895. 83. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom‘s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11:133-135. 84. Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2015;56:2637-2642. 85. Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186:146-149. 86. Rummel MJ, Lerchenmüller C, Hensel M, et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström‘s Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134:343-343. 87. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-1210. 88. Castillo JJ, Gustine J, Meid K, et al. Bendamustine and bortezomib-containing regimens produce higher response rates and more durable responses versus cyclophosphamide-based therapy in frontline Waldenstrommacroglobulinemia. Blood. 2017;130(Suppl.1):1488-1489. 89. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrommacroglobulinemia. Ann Hematol. 2018;97:1417-1425. 90. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenströmmacroglobulinemia: A meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol. 2016;105:118-126.doi: 10.1016/j.critrevonc.2016.06.004. 91. Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133:299-305. 92. Benevolo G, Ferrero S, Villivà N, et al. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). Blood. 2021;138(Supplement 1):48. doi: https://doi.org/424. 93. Chan WLW, Chong VCL, et al. Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis. Blood. 2021;138(Supplement 1):1358. doi: https://doi.org/10.1182/ blood-2021-150678. 94. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452-4457. 95. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom‘s macroglobulinemia. Clin Cancer Res. 2009;15(1):355-360. doi:10.1158/1078-0432.CCR08-0862. 96. Fouquet G, Guidez S, Petillon MO, et al. Lenalidomide is safe and active in Waldenströmmacroglobulinemia. Am J Hematol. 2015;90(11):1055-1059. doi: 10.1002/ajh.24175. 97. Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstrommacroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010;10:110-117. 98. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström‘s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):235-237. doi: 10.1016/j. clml.2013.02.014. 99. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830-3835.
RkJQdWJsaXNoZXIy NDA4Mjc=